Latest News
& Press Releases

Vertex and Arbor Biotechnologies extend partnership in precision gene editing.

Discover the benefits and challenges of relocating to a biopharma hot spot and find out the most important factors to consider when making your decision.

Alto reported positive data from a first-of-its-kind Phase IIb trial of major depressive disorder candidate ALTO-100.

BioXcel Therapeutics subsidiary OnkosXcel announced positive Phase II results in patients with small cell neuroendocrine metastatic castration-resistant (SCNC) prostate cancer.

Amarin Corporation wrestled with activist investor Sarissa Capital Management as the latter tried to replace Amarin’s current board of directors with its representatives.

Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.

Stay on top of what’s happening at JPM. BioSpace is covering all the key announcements all week.

In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.

Complete Genomics showcased its innovative sequencing capacity at the Biotech Showcase 2023, one of the year’s most important investor conferences.

The drugmaker’s presentation highlights its strong revenue growth, dominant vaccine business and expanding oncology portfolio.

Pfizer forecasts stable growth in the coming years, driven by a strong product push to cushion its non-COVID business and exclusivity losses.

In a presentation led by Robert J. Bradway, Amgen chairman and chief executive officer, the company covered recent acquisitions, Repatha and Lumakras updates, biosimilars and its broader financial outlook.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments